Literature DB >> 7870882

Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure.

M H Joseph1, S L Peters, J A Gray.   

Abstract

Latent inhibition (LI) is a cognitive process whereby repeated exposure of a stimulus without consequence impedes the formation of subsequent associations with that stimulus. A number of studies in the rat have reported that LI is impaired by moderate systemic doses of amphetamine, an effect believed to be mediated via dopamine (DA) release in the nucleus accumbens. We and others have reported that nicotine has a selective effect in releasing DA in the accumbens rather than the caudate nucleus. We have therefore examined the ability of nicotine to disrupt LI, using a conditioned emotional response paradigm. Pre-exposure of a tone stimulus impaired subsequent conditioning between that stimulus and mild footshock, as indexed by suppression of licking by the tone subsequently presented alone. This LI effect was prevented, by an effect confined to the pre-exposed group, by doses of 0.4 or 0.6 mg/kg nicotine SC, which are accumbens selective, given before pre-exposure and before conditioning. The effect of nicotine in disrupting LI was prevented by prior administration of haloperidol at a dose (0.5 mg/kg) reported to reverse the disruptive effect of amphetamine on LI. Although the amphetamine effect requires two administrations, the effect of two administrations of nicotine was reproduced by a single dose of nicotine given before conditioning, but not by a single dose before pre-exposure. The results are discussed in relation to studies in human control and schizophrenic subjects, which suggest that increased DA activity in humans is also associated with impaired LI.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870882     DOI: 10.1007/bf02246971

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  24 in total

1.  Antagonism of Low Dose Amphetamine Disruption of Latent Inhibition in Rats By Haloperidol, and By the 5Ht-3 Antagonist, Ondansetron: Warburton EC, Feldon J*, Weiner I*, Gray JA, Joseph MH MRC Brain, Behaviour and Psychiatry Research Group, Dept of Psychology, Institute of Psychiatry, London, SE5 8AF and *Dept of Psychology, University of Tel Aviv, Israel.

Authors: 
Journal:  J Psychopharmacol       Date:  1992-01       Impact factor: 4.153

2.  Nicotine Blocks Latent Inhibition in Rats: Evidence for Increased Functional Activity of Dopamine in the Mesolimbic System: Peters SL, Gray JA, Joseph MH MRC Brain, Behaviour and Psychiatry Research Group, Department of Psychology, Institute of Psychiatry, London SE5 8AF, UK.

Authors: 
Journal:  J Psychopharmacol       Date:  1992-01       Impact factor: 4.153

3.  Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man.

Authors:  N S Gray; A D Pickering; D R Hemsley; S Dawling; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Differential performance of acute and chronic schizophrenics in a latent inhibition task.

Authors:  I Baruch; D R Hemsley; J A Gray
Journal:  J Nerv Ment Dis       Date:  1988-10       Impact factor: 2.254

5.  Regionally specific effects of acute and chronic nicotine on rates of catecholamine and 5-hydroxytryptamine synthesis in rat brain.

Authors:  S N Mitchell; M P Brazell; M H Joseph; M S Alavijeh; J A Gray
Journal:  Eur J Pharmacol       Date:  1989-08-29       Impact factor: 4.432

6.  Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine.

Authors:  I Weiner; A Izraeli-Telerant; J Feldon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.

Authors:  M W Jann; S R Saklad; L Ereshefsky; A L Richards; C A Harrington; C M Davis
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

8.  Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder.

Authors:  P R Solomon; A Crider; J W Winkelman; A Turi; R M Kamer; L J Kaplan
Journal:  Biol Psychiatry       Date:  1981-06       Impact factor: 13.382

Review 9.  Neural substrates of latent inhibition: the switching model.

Authors:  I Weiner
Journal:  Psychol Bull       Date:  1990-11       Impact factor: 17.737

10.  Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.

Authors:  M F O'Neill; C T Dourish; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

View more
  11 in total

1.  Latent inhibition: interpretation of amphetamine effects in novel paradigms.

Authors:  M H Joseph
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

2.  Effects of nicotine and amphetamine on latent inhibition in human subjects.

Authors:  J C Thornton; S Dawe; C Lee; C Capstick; P J Corr; P Cotter; S Frangou; N S Gray; M A Russell; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

Review 3.  The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Authors:  Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-02-25       Impact factor: 4.530

4.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

5.  A pre-clinical study showing how dopaminergic drugs administered during pre-exposure can impair or facilitate latent inhibition.

Authors:  N A Schmajuk; J A Gray; J A Larrauri
Journal:  Psychopharmacology (Berl)       Date:  2004-08-13       Impact factor: 4.530

6.  Nicotine improves delayed recognition in schizophrenic patients.

Authors:  Carol S Myers; Olalla Robles; A Nancy Kakoyannis; Jay D Sherr; Matthew T Avila; Teresa A Blaxton; Gunvant K Thaker
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

7.  Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action.

Authors:  Cecilie Bay-Richter; Colm M P O'Tuathaigh; Gerard O'Sullivan; David M Heery; John L Waddington; Paula M Moran
Journal:  Int J Neuropsychopharmacol       Date:  2008-11-17       Impact factor: 5.176

8.  Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions.

Authors:  A S Killcross; A Dickinson; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

9.  Amphetamine-induced disruptions of latent inhibition are reinforcer mediated: implications for animal models of schizophrenic attentional dysfunction.

Authors:  A S Killcross; A Dickinson; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

10.  Dopamine D1 receptor involvement in latent inhibition and overshadowing.

Authors:  Andrew J D Nelson; Karen E Thur; Helen J Cassaday
Journal:  Int J Neuropsychopharmacol       Date:  2011-12-16       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.